Read by QxMD icon Read

Prodromal AD

Misato Yoshikawa, Yoshiyuki Soeda, Makoto Michikawa, Osborne F X Almeida, Akihiko Takashima
Hippocampal hyperactivity, ascribed to amyloid β (Aβ)-induced imbalances in neural excitation and inhibition, is found in patients with mild cognitive impairment, a prodromal stage of Alzheimer's disease (AD). To better understand the relationship between hippocampal hyperactivity and the molecular triggers of behavioral impairments in AD, we used Mn-enhanced MRI (MEMRI) to assess neuronal activity after subjecting mice to a task requiring spatial learning and memory. Depletion of endogenous tau in an amyloid precursor protein (APP) transgenic (J20) mouse line was shown to ameliorate hippocampal hyperactivity in J20 animals, tau depletion failed to reverse memory deficits associated with APP/Aβ overproduction...
2018: Frontiers in Neuroscience
Sarah Caughlin, Shikhar Maheshwari, Yuksel Agca, Cansu Agca, Aaron J Harris, Kristina Jurcic, Ken K-C Yeung, David F Cechetto, Shawn N Whitehead
BACKGROUND: Accumulation of simple gangliosides GM2 and GM3, and gangliosides with longer long-chain bases (d20:1) have been linked to toxicity and the pathogenesis of Alzheimer's disease (AD). Conversely, complex gangliosides, such as GM1, have been shown to be neuroprotective. Recent evidence using matrix-assisted laser desorption ionization imaging mass spectrometry (MALDI-IMS) has demonstrated that a-series gangliosides are differentially altered during normal aging, yet it remains unclear how simple species are shifting relative to complex gangliosides in the prodromal stages of AD...
March 12, 2018: Biochimica et Biophysica Acta
Roberta Ghidoni, Rosanna Squitti, Mariacristina Siotto, Luisa Benussi
The criteria for the clinical diagnosis of AD include the analysis of biomarkers of the underlying brain disease pathology; a set of cerebrospinal fluid (CSF) tests, amyloid-β1-42 (Aβ42), total-tau (t-tau), and phosphorylated tau (p-tau), are available and their performance in a clinical setting has been assessed in several studies. Thus, in dementia research, great advances have been made in the discovery of putative biomarkers; however, disappointingly, few of them have been translated into clinically applicable assays...
February 28, 2018: Journal of Alzheimer's Disease: JAD
Donghuan Lu, Karteek Popuri, Gavin Weiguang Ding, Rakesh Balachandar, Mirza Faisal Beg
Alzheimer's disease (AD) is one of the most common neurodegenerative diseases with a commonly seen prodromal mild cognitive impairment (MCI) phase where memory loss is the main complaint progressively worsening with behavior issues and poor self-care. However, not all individuals clinically diagnosed with MCI progress to AD. A fraction of subjects with MCI either progress to non-AD dementia or remain stable at the MCI stage without progressing to dementia. Although a curative treatment of AD is currently unavailable, it is extremely important to correctly identify the individuals in the MCI phase that will go on to develop AD so that they may benefit from a curative treatment when one becomes available in the near future...
February 21, 2018: Medical Image Analysis
Marci M Horn, Kristen M Kennedy, Karen M Rodrigue
Decline in associative memory abilities is a common cognitive complaint among older adults and is detectable in both normal aging and in prodromal Alzheimer's disease (AD). Subjective memory (SM) complaints may serve as an earlier marker of these mnemonic changes; however, previous research examining the predictive utility of SM to observed memory performance yielded inconsistent results. This inconsistency is likely due to other sources of variance that occur with memory decline such as mood/depression issues, presence of apolipoprotein E (APOE ε4) genotype, or beta-amyloid deposition...
February 2018: Psychology and Aging
Maria Catena Quattropani, Vittorio Lenzo, Vanessa Armieri, Antonella Filastro
AIM: Depression was associated to Alzheimer's disease (AD), even if its role as predictive symptom, risk factor or reactive factor remains unclear. The aim of this review was to investigate the relation between depression and AD. More specifically, we aimed to examine if depression may be a prodrome of AD or an early reaction to cognitive decline. METHODS: A systematic review based on the electronic bibliographic databases (PsycINFO, PubMed, Scopus, Web of Science, Web of Knowledge) was carried out on the scientific literature from 2010 to 2016...
January 2018: Rivista di Psichiatria
Sung-Wan Kim, Young-Chul Chung, Young-Shin Kang, Jae-Kyeong Kim, Ji-Eun Jang, Min Jhon, Ju-Yeon Lee, Jae-Min Kim, Il-Seon Shin, Jin-Sang Yoon
OBJECTIVE: To examine the reliability and validity of the Korean version of the 16-item Prodromal Questionnaire (KPQ-16) in non-help-seeking university students. METHODS: Among 2,246 university students participated in the initial screening, 257 subjects with KPQ-16 scores ≥4 were interviewed. The criteria for ultra-high risk (UHR) of psychosis of the Comprehensive Assessment of At-Risk Mental States (CAARMS) were the gold standard for diagnosis. An exploratory modified version of the questionnaire (mKPQ-16), to which three items from the Eppendorf Schizophrenia Inventory were added, was also used to compensate for items on thought and cognitive problems...
February 2018: Psychiatry Investigation
Andrea Katzorke, Julia B M Zeller, Laura D Müller, Martin Lauer, Thomas Polak, Jürgen Deckert, Martin J Herrmann
The verbal fluency task (VFT) is a well-established cognitive marker for mild cognitive impairment (MCI) in the prodromal stage of Alzheimer´s dementia (AD). The behavioral VFT performance of patients allows the prediction of dementia two years later. But effective compensatory mechanism might cover or reduce the predictive value of the VFT. Therefore the aim of this study is to measure the hemodynamic response during VFT in patients with mild cognitive impairment (MCI) to establish the hemodynamic response during the VFT as a screening instrument for the prediction of dementia...
February 11, 2018: Psychiatry Research
Corinna Porteri
BACKGROUND: The proposal of the new criteria for the diagnosis of Alzheimer's disease (AD) based on biomarker data is making possible a diagnosis of AD at the mild cognitive impairment (MCI) or predementia/prodromal- stage. Given the present lack of effective treatments for AD, the opportunity for the individuals to personally take relevant decisions and plan for their future before and if cognitive deterioration occurs is one the main advantages of an early diagnosis. MAIN BODY: Advance directives are largely seen as an effective tool for planning medical care in the event the subject becomes incompetent...
February 20, 2018: BMC Medical Ethics
Wenlu Yang, Xinyun Chen, David S Cohen, Eric R Rosin, Arthur W Toga, Paul M Thompson, Xudong Huang
Alzheimer's disease (AD) is a progressive, and often fatal, brain disease that causes neurodegeneration, resulting in memory loss as well as other cognitive and behavioral problems. Here, we propose a novel multimodal method combining independent components from MRI measures and clinical assessments to distinguish Alzheimer's patients or mild cognitive impairment (MCI) subjects from healthy elderly controls. 70 AD subjects (mean age: 77.15 ± 6.2 years), 98 MCI subjects (mean age: 76.91 ± 5.7 years), and 150 HC subjects (mean age: 75...
December 2017: International Journal of Clinical and Experimental Medicine
Mark Schweda, Anna Kögel, Claudia Bartels, Jens Wiltfang, Anja Schneider, Silke Schicktanz
BACKGROUND: Biomarker-supported testing for preclinical and prodromal Alzheimer's disease (AD) finds its way into clinical practice. Professional attitudes and practices regarding disclosure and ethical issues are controversial in many countries. OBJECTIVES: Against this background, the objective was to survey the actual practice and the attitudes of physicians in German hospitals and memory clinics in order to explore possible practical insecurities and ethical concerns...
2018: Journal of Alzheimer's Disease: JAD
Hugo Geerts, Athan Spiros, Patrick Roberts
BACKGROUND: Despite a tremendous amount of information on the role of amyloid in Alzheimer's disease (AD), almost all clinical trials testing this hypothesis have failed to generate clinically relevant cognitive effects. METHODS: We present an advanced mechanism-based and biophysically realistic quantitative systems pharmacology computer model of an Alzheimer-type neuronal cortical network that has been calibrated with Alzheimer Disease Assessment Scale, cognitive subscale (ADAS-Cog) readouts from historical clinical trials and simulated the differential impact of amyloid-beta (Aβ40 and Aβ42) oligomers on glutamate and nicotinic neurotransmission...
February 2, 2018: Alzheimer's Research & Therapy
Gesine Meyer, Maike Koch, Eva Herrmann, Jörg Bojunga, Klaus Badenhoop
PURPOSE: Several studies have shown a reduced quality of life (QoL) in patients with Addison's disease (AD), but investigations of QoL over a long-term course are lacking. Adrenal crises (AC) are life-threatening complications in AD. The purpose of this prospective study was to test whether the repeated use of QoL-questionnaires can detect prodromal periods of an AC. METHODS: 110 patients with AD were asked to complete the disease specific-QoL questionnaire AddiQoL and a short questionnaire about adverse events once monthly over a period of ten months...
January 31, 2018: Endocrine
Silvia Paola Caminiti, Tommaso Ballarini, Arianna Sala, Chiara Cerami, Luca Presotto, Roberto Santangelo, Federico Fallanca, Emilia Giovanna Vanoli, Luigi Gianolli, Sandro Iannaccone, Giuseppe Magnani, Daniela Perani
Background/aims: In this multicentre study in clinical settings, we assessed the accuracy of optimized procedures for FDG-PET brain metabolism and CSF classifications in predicting or excluding the conversion to Alzheimer's disease (AD) dementia and non-AD dementias. Methods: We included 80 MCI subjects with neurological and neuropsychological assessments, FDG-PET scan and CSF measures at entry, all with clinical follow-up. FDG-PET data were analysed with a validated voxel-based SPM method...
2018: NeuroImage: Clinical
Maria Serpente, Chiara Fenoglio, Sara Maria Giulia Cioffi, Emanuela Oldoni, Marina Arcaro, Andrea Arighi, Giorgio Giulio Fumagalli, Laura Ghezzi, Elio Scarpini, Daniela Galimberti
Herein, we performed a gene expression profiling in a cohort of 10 mild cognitive impairment (MCI), subdivided, according to the analysis of cerebrospinal fluid biomarkers, in prodromal Alzheimer's disease (AD) and non-AD MCI, as compared with 27 AD patients and 24 controls, in order to detect early gene expression alterations. We observed a significant upregulation of insulin (INS) and INS Receptor (INSR) expression levels in AD both prodromal and fully symptomatic, as compared with controls, but not in MCI subjects...
2018: Journal of Alzheimer's Disease: JAD
Tao Zhou, Kim-Han Thung, Xiaofeng Zhu, Dinggang Shen
In this paper, we aim to maximally utilize multimodality neuroimaging and genetic data to predict Alzheimer's disease (AD) and its prodromal status, i.e., a multi-status dementia diagnosis problem. Multimodality neuroimaging data such as MRI and PET provide valuable insights to abnormalities, and genetic data such as Single Nucleotide Polymorphism (SNP) provide information about a patient's AD risk factors. When used in conjunction, AD diagnosis may be improved. However, these data are heterogeneous (e.g., having different data distributions), and have different number of samples (e...
September 2017: Machine Learning in Medical Imaging
Flora H Duits, Gunnar Brinkmalm, Charlotte E Teunissen, Ann Brinkmalm, Philip Scheltens, Wiesje M Van der Flier, Henrik Zetterberg, Kaj Blennow
BACKGROUND: We investigated whether a panel of 12 potential novel biomarkers consisting of proteins involved in synapse functioning and immunity would be able to distinguish patients with Alzheimer's disease (AD) and patients with mild cognitive impairment (MCI) from control subjects. METHODS: We included 40 control subjects, 40 subjects with MCI, and 40 subjects with AD from the Amsterdam Dementia Cohort who were matched for age and sex (age 65 ± 5 years, 19 [48%] women)...
January 15, 2018: Alzheimer's Research & Therapy
Vijay R Varma, Anup M Oommen, Sudhir Varma, Ramon Casanova, Yang An, Ryan M Andrews, Richard O'Brien, Olga Pletnikova, Juan C Troncoso, Jon Toledo, Rebecca Baillie, Matthias Arnold, Gabi Kastenmueller, Kwangsik Nho, P Murali Doraiswamy, Andrew J Saykin, Rima Kaddurah-Daouk, Cristina Legido-Quigley, Madhav Thambisetty
BACKGROUND: The metabolic basis of Alzheimer disease (AD) is poorly understood, and the relationships between systemic abnormalities in metabolism and AD pathogenesis are unclear. Understanding how global perturbations in metabolism are related to severity of AD neuropathology and the eventual expression of AD symptoms in at-risk individuals is critical to developing effective disease-modifying treatments. In this study, we undertook parallel metabolomics analyses in both the brain and blood to identify systemic correlates of neuropathology and their associations with prodromal and preclinical measures of AD progression...
January 2018: PLoS Medicine
Philip S Insel, Oskar Hansson, R Scott Mackin, Michael Weiner, Niklas Mattsson
The objective of this study was to determine the cognitive and functional decline and development of brain injury in individuals progressing from preclinical (β-amyloid positive cognitively normal) to prodromal Alzheimer's disease (AD) (β-amyloid positive mild cognitive impairment [MCI]), and compare this with individuals who progress to MCI in the absence of significant amyloid pathology. Seventy-five cognitively healthy participants who progressed to MCI were followed for 4 years on average and up to 10 years...
December 27, 2017: Neurobiology of Aging
Lisa Miebach, Steffen Wolfsgruber, Ingo Frommann, Klaus Fließbach, Frank Jessen, Rachel Buckley, Michael Wagner
Background and Objectives: Cognitive complaints are discussed as early signs of Alzheimer's disease (AD). However, they are also very common in cognitively normal older adults and in patients with depression. Qualitative, interview-based approaches might be useful to identify those features of cognitive complaints specific for the experiences of cognitive decline in preclinical or prodromal AD versus those complaints typically reported by depressed patients. Research Design and Methods: A semi-structured interview was administered to 21 cognitively normal older adults (HC), 18 nondemented memory clinic patients (MC), and 11 patients with a major depression (MD), all above 55 years...
January 8, 2018: Gerontologist
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"